These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 38003967)
1. General Clinico-Pathological Characteristics in Glioblastomas in Correlation with p53 and Ki67. Sipos TC; Kövecsi A; Ovidiu-Ioan Ș; Zsuzsánna P Medicina (Kaunas); 2023 Oct; 59(11):. PubMed ID: 38003967 [No Abstract] [Full Text] [Related]
2. Diagnostic algorithm for pathological evaluation of gliomas in a resource-constrained setting. Jain S; Gupta P; Shankar KB; Singh R; Siraj F J Cancer Res Ther; 2023; 19(3):562-566. PubMed ID: 37470575 [TBL] [Abstract][Full Text] [Related]
3. Practice of IDH1, ATRX, and P53 Immunohistochemistry in Integrated Diagnosis of Adult Diffuse Gliomas: Single Center Study. Shabanzadeh Nejabad Z; Mabroukzadeh Kavari H; Saffar H; Tavangar SM; Sefidbakht S; Khoshnevisan A; Zare-Mirzaie A; Vasei M; Jafari E; Yaghmaii M; Saffar H Appl Immunohistochem Mol Morphol; 2023 Jul; 31(6):390-398. PubMed ID: 37278280 [TBL] [Abstract][Full Text] [Related]
4. Utility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas. Ikemura M; Shibahara J; Mukasa A; Takayanagi S; Aihara K; Saito N; Aburatani H; Fukayama M Histopathology; 2016 Aug; 69(2):260-7. PubMed ID: 26741321 [TBL] [Abstract][Full Text] [Related]
6. Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas. Nishikawa T; Watanabe R; Kitano Y; Yamamichi A; Motomura K; Ohka F; Aoki K; Hirano M; Kato A; Yamaguchi J; Maeda S; Kibe Y; Saito R; Wakabayashi T; Kato Y; Sato S; Ogino T; Natsume A; Ito I Brain Tumor Pathol; 2022 Jan; 39(1):14-24. PubMed ID: 34826036 [TBL] [Abstract][Full Text] [Related]
7. [Application of ATRX in diagnosis and prognostic evaluation of glioma]. Li Z; Piao YS; Zhang LY; Wang LM; Wang DD; Fu YJ; Cai YN; Lu DH Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):690-694. PubMed ID: 29050070 [No Abstract] [Full Text] [Related]
8. Pineal region glioblastomas display features of diffuse midline and non-midline gliomas. D'Amico RS; Zanazzi G; Wu P; Canoll P; Bruce JN J Neurooncol; 2018 Oct; 140(1):63-73. PubMed ID: 29992434 [TBL] [Abstract][Full Text] [Related]
9. The importance of IDH1, ATRX and WT-1 mutations in glioblastoma. Gülten G; Yalçın N; Baltalarlı B; Doğu G; Acar F; Doğruel Y Pol J Pathol; 2020; 71(2):127-137. PubMed ID: 32729303 [TBL] [Abstract][Full Text] [Related]
10. ATRX loss in glioneuronal tumors with neuropil-like islands indicates similarity to diffuse astrocytic tumors. Kakkar A; Nambirajan A; Kaur K; Kumar A; Mallick S; Suri V; Sarkar C; Kale SS; Garg A; Sharma MC J Neurooncol; 2016 Oct; 130(1):63-68. PubMed ID: 27469217 [TBL] [Abstract][Full Text] [Related]
11. Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas. Takano S; Ishikawa E; Sakamoto N; Matsuda M; Akutsu H; Noguchi M; Kato Y; Yamamoto T; Matsumura A Brain Tumor Pathol; 2016 Apr; 33(2):107-16. PubMed ID: 26968173 [TBL] [Abstract][Full Text] [Related]
12. Radiogenomics correlation between MR imaging features and major genetic profiles in glioblastoma. Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST Eur Radiol; 2018 Oct; 28(10):4350-4361. PubMed ID: 29721688 [TBL] [Abstract][Full Text] [Related]
13. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834 [TBL] [Abstract][Full Text] [Related]
14. Significance of H3K27M mutation with specific histomorphological features and associated molecular alterations in pediatric high-grade glial tumors. Bozkurt SU; Dagcinar A; Tanrikulu B; Comunoglu N; Meydan BC; Ozek M; Oz B Childs Nerv Syst; 2018 Jan; 34(1):107-116. PubMed ID: 29063957 [TBL] [Abstract][Full Text] [Related]
15. Barange M; Epari S; Gurav M; Shetty O; Sahay A; Shetty P; Goda J; Moyiadi A; Gupta T; Jalali R Neurol India; 2021; 69(1):126-134. PubMed ID: 33642283 [TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical ATRX expression is not a surrogate for 1p19q codeletion. Yamamichi A; Ohka F; Aoki K; Suzuki H; Kato A; Hirano M; Motomura K; Tanahashi K; Chalise L; Maeda S; Wakabayashi T; Kato Y; Natsume A Brain Tumor Pathol; 2018 Apr; 35(2):106-113. PubMed ID: 29550880 [TBL] [Abstract][Full Text] [Related]
17. Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas. Wong QH; Li KK; Wang WW; Malta TM; Noushmehr H; Grabovska Y; Jones C; Chan AK; Kwan JS; Huang QJ; Wong GC; Li WC; Liu XZ; Chen H; Chan DT; Mao Y; Zhang ZY; Shi ZF; Ng HK Mod Pathol; 2021 Jul; 34(7):1245-1260. PubMed ID: 33692446 [TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of ATRX in gliomas. Jalal JA; Rowandizy AIS; Ismael AT Cell Mol Biol (Noisy-le-grand); 2020 Aug; 66(7):131-135. PubMed ID: 33287933 [TBL] [Abstract][Full Text] [Related]
19. Prediction of Ki-67 labeling index, ATRX mutation, and MGMT promoter methylation status in IDH-mutant astrocytoma by morphological MRI, SWI, DWI, and DSC-PWI. Yang X; Hu C; Xing Z; Lin Y; Su Y; Wang X; Cao D Eur Radiol; 2023 Oct; 33(10):7003-7014. PubMed ID: 37133522 [TBL] [Abstract][Full Text] [Related]
20. ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma. Babikir H; Wang L; Shamardani K; Catalan F; Sudhir S; Aghi MK; Raleigh DR; Phillips JJ; Diaz AA Genome Biol; 2021 Nov; 22(1):311. PubMed ID: 34763709 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]